Halting the progression of chronic nephropathy.
The incidence of end-stage renal disease (ESRD) is increasing worldwide. In the United States alone, there were 372,000 patients requiring renal replacement therapy in the year 2000 and is expected to rise to 650,000 by the year 2010. The trends in Europe and Japan are forecasted to follow a similar path. These increases represent a significant burden to countries worldwide; not only due to the financial costs of providing ESRD care, but also because of lost productivity and significant morbidity and mortality for the affected patients. There is clearly a pressing need for the aggressive identification and early treatment of patients with nephropathy to prevent progression to ESRD. Research in the last 25 yr has made great advances in the understanding of the progression of chronic renal disease in diabetic and nondiabetic proteinuric nephropathy. There are now effective treatment options that can slow the progression of chronic nephropathies in many individuals, and ongoing research has raised the tantalizing prospect of the reversal of renal disease progression.
Campbell
Ruth C
RC
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Ruggenenti
Piero
P
Remuzzi
Giuseppe
G
D002908:Chronic Disease; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007674:Kidney Diseases / Q000503:physiopathology* / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000517:prevention & control